Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
173 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Indolent Lymphoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Indolent Lymphoma - Pipeline Review, H1 2015', provides an overview of the Indolent Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Indolent Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Indolent Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Indolent Lymphoma Overview 9 Therapeutics Development 10 Pipeline Products for Indolent Lymphoma - Overview 10 Pipeline Products for Indolent Lymphoma - Comparative Analysis 11 Indolent Lymphoma - Therapeutics under Development by Companies 12 Indolent Lymphoma - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Unknown Stage Products 17 Indolent Lymphoma - Products under Development by Companies 18 Indolent Lymphoma - Companies Involved in Therapeutics Development 20 Amgen Inc. 20 Astellas Pharma Inc. 21 Bayer AG 22 BioMedics Japan Inc. 23 Biothera, Inc. 24 Boehringer Ingelheim GmbH 25 Celgene Corporation 26 Eagle Pharmaceuticals, Inc. 27 Emergent BioSolutions Inc. 28 F. Hoffmann-La Roche Ltd. 29 Gilead Sciences, Inc. 30 Incyte Corporation 31 Infinity Pharmaceuticals, Inc. 32 Juno Therapeutics Inc. 33 Kite Pharma, Inc. 34 MedImmune, LLC 35 Merck & Co., Inc. 36 Merck KGaA 37 MorphoSys AG 38 Pharmacyclics, Inc. 39 Sandoz Inc. 40 Indolent Lymphoma - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 SAssessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 bendamustine hydrochloride - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 bendamustine hydrochloride SI - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BI-836826 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 blinatumomab - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 BM-ca - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 copanlisib - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 DI-B4 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 duvelisib - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 GS-9973 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 ibrutinib - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 idelalisib - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Imprime PGG - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 INCB-050465 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 INCB-39110 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 INCB-40093 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 JCAR-015 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 KTE-C19 CAR - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 lenalidomide - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 MEDI-551 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 MOR-208 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 obinutuzumab - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 otlertuzumab - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 rituximab biosimilar - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 vorinostat - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Indolent Lymphoma - Recent Pipeline Updates 104 Indolent Lymphoma - Dormant Projects 158 Indolent Lymphoma - Discontinued Products 159 Indolent Lymphoma - Product Development Milestones 160 Featured News & Press Releases 160 Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 160 Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 160 Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 161 Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 162 Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 164 Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 166 Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 167 Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 168 Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 169 Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 171 Appendix 172 Methodology 172 Coverage 172 Secondary Research 172 Primary Research 172 Expert Panel Validation 172 Contact Us 172 Disclaimer 173
List of Tables Number of Products under Development for Indolent Lymphoma, H1 2015 10 Number of Products under Development for Indolent Lymphoma - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Comparative Analysis by Late Stage Development, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Unknown Stage Development, H1 2015 17 Products under Development by Companies, H1 2015 18 Products under Development by Companies, H1 2015 (Contd..1) 19 Indolent Lymphoma - Pipeline by Amgen Inc., H1 2015 20 Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H1 2015 21 Indolent Lymphoma - Pipeline by Bayer AG, H1 2015 22 Indolent Lymphoma - Pipeline by BioMedics Japan Inc., H1 2015 23 Indolent Lymphoma - Pipeline by Biothera, Inc., H1 2015 24 Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 25 Indolent Lymphoma - Pipeline by Celgene Corporation, H1 2015 26 Indolent Lymphoma - Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 27 Indolent Lymphoma - Pipeline by Emergent BioSolutions Inc., H1 2015 28 Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 29 Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2015 30 Indolent Lymphoma - Pipeline by Incyte Corporation, H1 2015 31 Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 32 Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2015 33 Indolent Lymphoma - Pipeline by Kite Pharma, Inc., H1 2015 34 Indolent Lymphoma - Pipeline by MedImmune, LLC, H1 2015 35 Indolent Lymphoma - Pipeline by Merck & Co., Inc., H1 2015 36 Indolent Lymphoma - Pipeline by Merck KGaA, H1 2015 37 Indolent Lymphoma - Pipeline by MorphoSys AG, H1 2015 38 Indolent Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2015 39 Indolent Lymphoma - Pipeline by Sandoz Inc., H1 2015 40 Assessment by Monotherapy Products, H1 2015 41 Number of Products by Stage and Target, H1 2015 43 Number of Products by Stage and Mechanism of Action, H1 2015 45 Number of Products by Stage and Route of Administration, H1 2015 47 Number of Products by Stage and Molecule Type, H1 2015 49 Indolent Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 104 Indolent Lymphoma - Dormant Projects, H1 2015 158 Indolent Lymphoma - Discontinued Products, H1 2015 159
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
